AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23510124
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily for 90 days
Trial: 23510124
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 90 days
Trial: 15587537
Drug: Dorsal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal block and ring block in combination with concentrated oral sucrose
Trial: 15587537
Drug: Concentrated oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated oral sucrose alone
Trial: 11717622
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of oral beta(2)-adrenergic receptor agonists (beta(2)-AG) for 2 weeks
Trial: 11717622
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion with heart rate adjusted to 90 beats/min
Trial: 9137794
Drug: Standard-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose cytarabine (SDAC)
Trial: 22287757
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HDAC)
Trial: 3595574
Drug: Pancuronium (cumulative-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (cumulative-dose method)
Trial: 3595574
Drug: Tubocurarine (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine (single-dose method)
Trial: 3595574
Drug: Tubocurarine (cumulative-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine (cumulative-dose method)
Trial: 27473311
Drug: Mindfulness-Based Art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Art Therapy (MBAT)
Trial: 29122108
Drug: Non-insulin-treated T2DM
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin-treated T2DM
Trial: 29122108
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (insulin initiators and non-initiators)
Trial: 20371683
Drug: CHOP (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (conventional chemotherapy)
Trial: 16983932
Drug: Azelnidipine (8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine (8-16 mg daily)
Trial: 21929736
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg daily)
Trial: 8232485
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (250 mg every six hours for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days)
Trial: 8232485
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (1 mg per kilogram for 14 days)
Trial: 8232485
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone compared to placebo
Trial: 18788652
Drug: Nonpharmacological sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological sleep therapy for 6 weeks
Trial: 16038599
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus fluoxetine combination therapy
Trial: 22035648
Drug: Quetiapine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine monotherapy
Trial: 10067800
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 10-20 mg once a day)
Trial: 7669484
Drug: Ro 40‐5967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40‐5967 (50 mg daily)
Trial: 7669484
Drug: Ro 40‐5967
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 40‐5967 (100 mg daily)
Trial: 7669484
Drug: Digoxin alone
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin alone (0.375 mg daily)
Trial: 7475716
Drug: Control (Meningococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Meningococcal vaccine)
Trial: 26503021
Drug: Early AED
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early AED withdrawal starting 4 months after surgery, with intended complete cessation of drugs after 12 months.
Trial: 21039927
Drug: Zilpaterol-HCl (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilpaterol-HCl (60 mg/day)
Trial: 17545078
Drug: Intravenous hemocoagulase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hemocoagulase acutus at 2 U
Trial: 11061989
Drug: 260 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 260 mg/d ascorbate plus 14 mg/d iron
Trial: 24114551
Drug: Personalized text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized text messaging intervention (4-6 messages daily for 4 days)
Trial: 10355212
Drug: Pain treatment
RxNorm normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain treatment
Trial: 10355212
Drug: Analgesics 'as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics 'as needed'
Trial: 8594426
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard heparin
Trial: 8594426
Drug: Subcutaneous low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous low-molecular-weight heparin
Trial: 27456835
Drug: Microvascular disease
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microvascular disease (retinal photocoagulation therapy)
Trial: 10585165
Drug: Acute creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute creatine loading (25 g per day for 4 days)
Trial: 10585165
Drug: Longer-term creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer-term creatine supplementation (5 g of creatine per day for 2 months)
Trial: 10585165
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g per day for 2 months)
Trial: 25669611
Drug: dezocine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezocine 0.1 mg/kg
Trial: 24385131
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of zolpidem
Trial: 25734733
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of lorazepam
Trial: 17709293
Drug: Visual analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual analogue scale for sedative effects
Trial: 29122087
Drug: 8 mg/mL
RxNorm normalized name: valine 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/mL triamcinolone
Trial: 29122087
Drug: 16 mg/mL
RxNorm normalized name: glycerin 16 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/mL triamcinolone
Trial: 23161645
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral prednisone given daily for 10 days
Trial: 18355422
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg alone
Trial: 21810257
Drug: Sinvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinvastatin 40 mg plus ezetimibe 10 mg plus fiber (25 g)
Trial: 21810257
Drug: Sinvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinvastatin 40 mg plus ezetimibe 10 mg
Trial: 19369367
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 5 mg x kg(‐1) x d(‐1)
Trial: 19369367
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 70 mg x kg(‐1) x d(‐1)
Trial: 22975536
Drug: β‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐blockers
Trial: 2882775
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel antagonists
Trial: 11806300
Drug: Potassium channel
RxNorm normalized name: Potassium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium channel agonists
Trial: 11806300
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of platelet aggregation
Trial: 11806300
Drug: Antibiotics against
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics against intra‐cellular germs
Trial: 9923567
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (50 mg/m2 daily for 21 days)
Trial: 7994805
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Streptokinase and TPA)
Trial: 29437621
Drug: Murepavadin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murepavadin (single ascending dose)
Trial: 29437621
Drug: Murepavadin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murepavadin (multiple ascending doses)
Trial: 26377496
Drug: Usual transplant
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual transplant patient education plus ten additional weekly 30‐min education/counseling sessions about immunosuppressive drugs and behavioral changes
Trial: 21792296
Drug: Intramuscular ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ACTH gel
Trial: 21792296
Drug: Subcutaneous ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous ACTH gel
Trial: 18055864
Drug: Decitabine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (100 mg/m² per course every 4 weeks)
Trial: 10487558
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no xerostomy prevention therapy)
Trial: 8533995
Drug: Mesalamine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 0.8 g/d
Trial: 8533995
Drug: Mesalamine 1.6
RxNorm normalized name: Mesalamine 1.6 g gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1.6 g/d
Trial: 8533995
Drug: Mesalamine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 0.8 g/d (intention-to-treat)
Trial: 8533995
Drug: Mesalamine 1.6
RxNorm normalized name: Mesalamine 1.6 g gastro-resistant and prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 1.6 g/d (intention-to-treat)
Trial: 30877658
Drug: 6α‐methylprednisolone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6α‐methylprednisolone acetate (MA) 40 mg
Trial: 30877658
Drug: triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamcinolone acetonide (TA) 40 mg
Trial: 25131073
Drug: rATG (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rATG (multiple doses starting intraoperatively)
Trial: 25131073
Drug: ALEM (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALEM (30 mg intraoperatively)
Trial: 20817153
Drug: CBT +
RxNorm normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBT + DCS (25 or 50 mg)
Trial: 9505188
Drug: ceftibuten 400
RxNorm normalized name: ceftibuten 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftibuten 400 mg once daily
Trial: 9505188
Drug: clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin 500 mg twice daily
Trial: 8540613
Drug: Neoadjuvant combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant combination therapy with flutamide and an LHRH agonist for 3 months
Trial: 24320906
Drug: Herbal dentifrice
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal dentifrice (Hi Ora K, The Himalaya Drug Company)
Trial: 24320906
Drug: Placebo dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dentifrice (The Himalaya Drug Company)
Trial: 20199402
Drug: C (bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (bathing and cream)
Trial: 20199402
Drug: WG +
RxNorm normalized name: Warfarin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WG + C (bathing with wash gel plus cream)
Trial: 11277374
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg per day for up to 9 days in a reducing schedule)
Trial: 9973793
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (group A)
Trial: 9973793
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (group B)
Trial: 7603075
Drug: Amlodipine (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (11 mg intravenous dose)
Trial: 29155973
Drug: Tapering MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering MTX (double-blind)
Trial: 22824474
Drug: AS03A-adjuvanted A/California/7/2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days
Trial: 22824474
Drug: AS03A-adjuvanted A/California/7/2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A-adjuvanted A/California/7/2009 H1N1 vaccine (1.9 μg HA) administered at 21 days or 6 months
Trial: 30104006
Drug: CTRT (RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRT (RT + weekly cisplatin), n = 94
Trial: 26632091
Drug: IPX066 (carbidopa-levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX066 (carbidopa-levodopa extended-release capsules)
Trial: 25634565
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone (2 mg/kg loading dose, 1 mg/kg/d continuous infusion on days 1‐7, tapered on days 8‐14)
Trial: 24231627
Drug: Pemetrexed alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed alone (500 mg/m2)
Trial: 24231627
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) with cetuximab
Trial: 24231627
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) alone
Trial: 3341247
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and mineral supplement
Trial: 1764940
Drug: Insertion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertion of NORPLANT implants with scalpel
Trial: 1764940
Drug: Insertion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insertion of NORPLANT implants without scalpel
Trial: 28552382
Drug: Icatibant 30
RxNorm normalized name: icatibant 30 MG in 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant 30 mg
Trial: 19542866
Drug: TDF/FTC 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC 300 mg/200 mg with lopinavir/ritonavir 800 mg/200 mg
Trial: 19542866
Drug: ABC/3TC 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/3TC 600 mg/300 mg with lopinavir/ritonavir 800 mg/200 mg
Trial: 15147545
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone)
Trial: 15147545
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone)
Trial: 15147545
Drug: Preoperative androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative androgen deprivation in subpopulation with PSA < 35.6 ng/mL and clinical stage B or C cancers
Trial: 11120904
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (1 mg/kg/day for three months, then 10 mg/day for three months)
Trial: 10092565
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment (n = 56)
Trial: 7407516
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate and propranolol (380 mg/day) while not smoking
Trial: 27456328
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention involving GPs and HCAs conducting checklist-based interviews and medication reconciliation with the aid of a CDSS.
Trial: 19552963
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 3-12 mg/day
Trial: 12692056
Drug: Interferon 3
RxNorm normalized name: interferon beta-1b 0.3 MG [Betaseron]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A
Trial: 10726917
Drug: Control (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (insulin infusion using euglycemic clamp protocol for 240 minutes at a rate of 40 mU/m2/min for young and 34 mU/m2/min for old)
Trial: 10726917
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) coinfused with insulin
Trial: 10726917
Drug: Control (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (insulin infusion)
Trial: 1335641
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine, strain HM175, 360 ELISA units (El.U) on days 0 and 28
Trial: 1335641
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14 (abbreviated schedule)
Trial: 30151212
Drug: Mirogabalin 50
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 50 and 75 mg single dose
Trial: 30049303
Drug: Mirogabalin 15
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 15 mg
Trial: 30151212
Drug: Mirogabalin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin (various doses)
Trial: 26996385
Drug: Cyclophosphamide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide + Veliparib (60 mg daily)
Trial: 26996385
Drug: Cyclophosphamide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide alone (50 mg once daily)
Trial: 15892594
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 40mg once daily
Trial: 12699438
Drug: GHRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (1 micro g/kg)
Trial: 11220764
Drug: Full-dose PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose PRP-T Hib vaccine
Trial: 11220764
Drug: Half-dose PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose PRP-T Hib vaccine
Trial: 11220764
Drug: Half-dose PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose PRP-T Hib vaccine combined with DTP
Trial: 11220764
Drug: One-third-dose PRP-T
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-third-dose PRP-T Hib vaccine combined with DTP
Trial: 23660990
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg droperidol
Trial: 10425409
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg droperidol
Trial: 6815974
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine
Trial: 6815974
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg morphine
Trial: 1486261
Drug: 1,3,7-trimethylxanthine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,3,7-trimethylxanthine (800 mg in caffeinated coffee)
Trial: 27930531
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline solution)